Cytokine-adjuvanted HIV-DNA vaccination strategies

Franco Lori; David B Weiner; Sandra A Calarota; Laurene M Kelly; Julianna Lisziewicz

doi:10.1007/s00281-006-0047-y

Cytokine-adjuvanted HIV-DNA vaccination strategies

Springer Semin Immunopathol. 2006 Nov;28(3):231-8. doi: 10.1007/s00281-006-0047-y. Epub 2006 Oct 20.

Authors

Franco Lori¹, David B Weiner, Sandra A Calarota, Laurene M Kelly, Julianna Lisziewicz

Affiliation

¹ Research Institute for Genetic and Human Therapy (RIGHT), Pavia, Italy. [email protected]

PMID: 17053912
DOI: 10.1007/s00281-006-0047-y

Abstract

This review highlights some of the most common cytokines currently being tested as adjuvants in HIV-1-DNA vaccine regimens. We discuss their use in both the prophylactic and therapeutic setting. Finally, we describe a novel dendritic cell-targeted vaccine candidate for HIV-1 treatment and prevention called DermaVir and explore the combination of the DermaVir technology with the cytokine adjuvants interleukin-7 and interleukin-15.

Publication types

Review

MeSH terms

AIDS Vaccines* / immunology
AIDS Vaccines* / therapeutic use
Adjuvants, Immunologic*
Animals
Antiretroviral Therapy, Highly Active
Cytokines / immunology*
HIV Antibodies / biosynthesis
HIV Antibodies / immunology
HIV Infections / immunology
HIV Infections / prevention & control*
HIV Infections / therapy*
Humans
Vaccines, DNA* / immunology
Vaccines, DNA* / therapeutic use

Substances

AIDS Vaccines
Adjuvants, Immunologic
Cytokines
DermaVir
HIV Antibodies
Vaccines, DNA